Accelerating Paediatric Cancer Precision Medicine With Mass Spectrometry-based Proteomics
Funder
National Health and Medical Research Council
Funding Amount
$79,041.00
Summary
The Zero Childhood Cancer (ZERO) Program measures the DNA and RNA in individual cancer samples and then recommends a unique treatment plan for each child. In this study, we will measure the proteome (ie the set of proteins) in ~100 ZERO cancer samples at the Children's Medical Research Institute's ProCan. The goal of this project is to assess the value of protein data for informing drug treatment recommendations and finding new drug targets for children diagnosed with a cancer of poor prognosis.
Biosensor Based Clinical-decision Support For Patients With Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$691,933.00
Summary
Heart Failure (HF) is a progressive disease and a major global public health concern. HF accounts for a substantial number of hospitalisations, major healthcare resource utilisation and costs. We aim to engineer biosensor platform to stratify the risk in HF patients will revolutionise current management of HF by providing the cardiologist information to risk stratify patients based on protein signature. This will lead to a substantial paradigm shift in clinical practice.
Serum Neurofilament Light As A Biomarker To Improve Management Of Mild Traumatic Brain Injuries
Funder
National Health and Medical Research Council
Funding Amount
$1,092,781.00
Summary
There is increasing awareness that mild traumatic brain injuries (mTBIs), such as concussions, can lead to persistent or permanent neurological symptoms. Nonetheless, the identification and management of mTBIs remains notoriously difficult. In this proposal, we will assess exactly how a novel blood test can be implemented to assist in mTBI diagnosis, and the identification and management of individuals at risk of suffering persistent or chronic neurological problems.
We are studying human amnion epithelial cells (AECs) as a new therapy for stroke. Here if we find the protective effects of AECs are unaffected by a 'clot-buster' drug,we will broaden our planned Phase II trial of AECs to include patients that have received clot lysis therapy. Further, as we suspect that AECs exert their effects via release of nanoparticles called 'exosomes', we will test whether exosomes given intravenously or intranasally are similarly protective.
Precision Molecular Diagnostics Of Single Cells By Imaging Flow Cytometry
Funder
National Health and Medical Research Council
Funding Amount
$875,110.00
Summary
We have invented a highly sensitive, new method to count and evaluate chromosomes inside cancer cells. With this world-first method we can detect abnormal chromosomes when fewer than 1 cell in 1,000 is affected. We will refine the method for assessment of blood cancers and chromosome disorders such as trisomy 21 (Down Syndrome), and commence pre-clinical testing. This is a critical step towards translating this methodology into a validated test to significantly benefit human health.
Staying Connected: Personalising Stroke Recovery And Rehabilitation Through New Technologies For People With Stroke Living At Home.
Funder
National Health and Medical Research Council
Funding Amount
$1,730,999.00
Summary
One in 4 people experience a stroke. On return home the person with stroke is challenged to sense, move, think, and engage in valued activities with an altered brain and body. Yet the current approach to ongoing recovery is limited. We propose to: monitor for markers of recovery using personalised sensors and artificial intelligence; deliver bursts of therapy at point of need, at home; and provide feedback through new technologies and a central hub...to stay connected, and to recover at home.
DImensional Attention MOdelling For Neglect Detection (DIAMOND): A Novel Application For Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$513,483.00
Summary
One in three people experience neglect disorder after brain injury, where half of their visual world appears missing. Neglect is a persistent and distressing cognitive problem impacting all aspects of daily life, and is typically under-diagnosed and poorly treated. We have built a novel 3D technology platform for precision detection of neglect, and for informing personalised treatment options. This systematic feasibility project will establish early evidence for advanced neglect assessment.
Harnessing The Dual Roles Of Pericytes To Improve Stroke Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$853,943.00
Summary
Pericytes are cells that are in the walls of capillaries - the smallest blood vessels. Pericytes control blood flow and help promote recovery after injury. In stroke, pericytes squeeze the capillary shut, limiting the amount of energy getting to the brain. This proposal will use innovative techniques to understand how pericytes limit blood flow and also how we can utilise pericytes to improve brain recovery after stroke. This will allow us to identify new potential treatment options for stroke.
Using A National Level Multi-registry Analysis To Determine Whether Prescribed Anti-platelet Therapies Post-stroke Can Modify The Risk Of Cognitive Decline Or Dementia
Funder
National Health and Medical Research Council
Funding Amount
$446,302.00
Summary
Stroke survivors are at risk of dementia. Blood brain barrier damage after stroke may allow drugs in the bloodstream, which can be toxic to brain cells, to enter the brain. Clopidogrel, a drug commonly used after stroke, blocks a receptor essential for brain repair. After stroke, clopidogrel may access the brain and compromise repair processes, increasing the risk of dementia. We will link use of clopidogrel to the risk of dementia after stroke, using national Swedish health registry data.
Discovering How A Novel Anti-malarial Drug Series Rapidly Kills Parasites
Funder
National Health and Medical Research Council
Funding Amount
$672,971.00
Summary
We have developed a new set of highly potent anti-malarial drugs but we do not know how they work. Identifying how these compounds work is important for improving their effectiveness and safety. We will discover how these drugs kill parasites by using a number of cutting edge methods that could also be useful for discovering how other drugs work. Data generated will progress these compounds along the drug development pipeline which urgently needs a constant supply of new antimalarials.